942999-69-1Relevant academic research and scientific papers
LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS
-
Paragraph 1095, (2014/07/23)
Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.
Discovery of a potent, selective, and orally efficacious pyrimidinooxazinyl bicyclooctaneacetic acid diacylglycerol acyltransferase-1 inhibitor
Birch, Alan M.,Birtles, Susan,Buckett, Linda K.,Kemmitt, Paul D.,Smith, Graham J.,Smith, Tim J. D.,Turnbull, Andrew V.,Wang, Steven J. Y.
experimental part, p. 1558 - 1568 (2010/01/07)
Inhibition of DGAT-1 is increasingly seen as an attractive mechanism with the potential for treatment of obesity and other elements of the metabolic syndrome. We report here a bicyclooctaneacetic acid derivative in the pyrimidinooxazine structural class o
PYRIMIDO- [4, 5-B] -OXAZINES FOR USE AS DGAT INHIBITORS
-
Page/Page column 36-37, (2008/06/13)
Formula (I). Compounds of formula (I) or salts thereof, wherein A1, and R1 to R5 are as defined in the specification, are DGAT-1 inhibitors and are thereby useful in the treatment of, for example, obesity. Processes to make compounds of formula (I) are also described.
